The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
p300/CBP and cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS
Allfrey, V. G., Faulkner, R., & Mirsky, A. E. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.51.5.786 · Cited by 2,639
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
Petrif, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G.-J. B., Goodman, R. H., Peters, D. J. M., et al. (1995) · Nature · doi:10.1038/376348a0 · Cited by 1,217
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204 · cited 3×
“After DNA damage, p53 is activated by phosphorylation by various kinases and acetylation at specific amino-acid residues by p300/CBP (Sakaguchi et al., 1998). p53 acetylation is thought to promote target gene activation by increasing the stability of the p53–p300–DNA complex (Gu and Roeder, 1997;…”
BackgroundInfluentialAcetylation: a regulatory modification to rival phosphorylation?
Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1176 · Cited by 1,160
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Chan, H. M., & La Thangue, N. B. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2363 · Cited by 1,092
Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., DeCaprio, J. A., Lawrence, J. B., & Livingston, D. M. (1994) · Genes & Development · doi:10.1101/gad.8.8.869 · Cited by 1,045
Yao, T.-P., Oh, S. P., Fuchs, M., Zhou, N.-D., Ch'ng, L.-E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., & Eckner, R. (1998) · Cell · doi:10.1016/s0092-8674(00)81165-4 · Cited by 1,014
Borrow, J., Stanton, V. P., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S. K., Civin, C. I., Disteche, C., Dubé, I., Frischauf, A. M., et al. (1996) · Nature Genetics · doi:10.1038/ng0996-33 · Cited by 771
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694 · cited 1×
“…(2004) 23, 4225–4231 & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $30.00 www.nature.com/onc (Gu and Roeder, 1997; Boyes et al., 1998; Munshi et al., 1998; Sakaguchi et al., 1998; Bannister et al., 2000; Martinez-Balbas et al., 2000; Marzio et al., 2000; Tomita…”
BackgroundInfluentialBinding and modulation of p53 by p300/CBP coactivators
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693
Regulation of E2F1 activity by acetylation
Martínez-Balbás, M. A., Bauer, U.-M., Nielsen, S. J., Brehm, A., & Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.662 · Cited by 671
Recruitment of p300/CBP in p53-Dependent Signal Pathways
Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 669
Mutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587
Self-citationPolyubiquitination of p53 by a Ubiquitin Ligase Activity of p300
Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., & Livingston, D. M. (2003) · Science · doi:10.1126/science.1080386 · Cited by 459
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP
Kung, A. L., Rebel, V. I., Bronson, R. T., Ch'ng, L.-E., Sieff, C. A., Livingston, D. M., & Yao, T.-P. (2000) · Genes & Development · doi:10.1101/gad.14.3.272 · Cited by 440
Espinosa, J. M., & Emerson, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00283-0 · Cited by 439
Merika, M., Williams, A. J., Chen, G., Collins, T., & Thanos, D. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80028-3 · Cited by 435
p300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414 · cited 1×
“…p300 effect. p300/CBP modulate the p53 pathway at multiple levels (reviewed in Grossman, 2001). p300 contributes to maintaining p53 stability by regulating its ubiquitination and degradation, through both mdm2-dependent and - independent mechanisms (Grossman et al., 1998, 2003; Kawai et al., 2001).”
BackgroundConjunction dysfunction: CBP/p300 in human disease
Giles, R. H., Peters, D. J. M., & Breuning, M. H. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01438-3 · Cited by 403
The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300
Patel, D., Huang, S., Baglia, L. A., & McCance, D. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.18.5061 · Cited by 374
Physical and Functional Interaction of SMADs and p300/CBP
Pouponnot, C., Jayaraman, L., & Massagué, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.36.22865 · Cited by 349
CBP-induced stimulation of c-Fos activity is abrogated by E1A.
Bannister, A. J., & Kouzarides, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00157.x · Cited by 337
Takemura, R., Okabe, S., Umeyama, T., Kanai, Y., Cowan, N. J., & Hirokawa, N. (1992) · Journal of Cell Science · doi:10.1242/jcs.103.4.953 · Cited by 326
RUNX transcription factors as key targets of TGF-β superfamily signaling
Ito, Y., & Miyazono, K. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00007-8 · Cited by 324
Acetylation of HMG I(Y) by CBP Turns off IFNβ Expression by Disrupting the Enhanceosome
Munshi, N., Merika, M., Yie, J., Senger, K., Chen, G., & Thanos, D. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80145-8 · Cited by 321
DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes
Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., Fontemaggi, G., Fanciulli, M., Schiltz, L., Blandino, G., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00431-8 · Cited by 319
Sobulo, O. M., Borrow, J., Tomek, R., Reshmi, S., Harden, A., Schlegelberger, B., Housman, D., Doggett, N. A., Rowley, J. D., & Zeleznik-Le, N. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8732 · Cited by 319
Oike, Y. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.387 · Cited by 305
p300 and CBP: Partners for life and death
Giordano, A., & Avantaggiati, M. L. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199911)181:2<218::aid-jcp4>3.0.co;2-5 · Cited by 291
Tumors in Rubinstein‐Taybi syndrome
Miller, R. W., & Rubinstein, J. H. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560125 · Cited by 283
Acetylation control of the retinoblastoma tumour-suppressor protein
Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C., & Thangue, N. B. L. (2001) · Nature Cell Biology · doi:10.1038/35083062 · Cited by 282
Zimmermann, H., Degenkolbe, R., Bernard, H.-U., & O’Connor, M. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6209-6219.1999 · Cited by 282
p300/CBP/p53 interaction and regulation of the p53 response
Grossman, S. R. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02226.x · Cited by 263
Ida, K., Kitabayashi, I., Taki, T., Taniwaki, M., Noro, K., Yamamoto, M., Ohki, M., & Hayashi, Y. (1997) · Blood · doi:10.1182/blood.v90.12.4699 · Cited by 259
Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal
Rebel, V. I., Kung, A. L., Tanner, E. A., Yang, H., Bronson, R. T., & Livingston, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232568499 · Cited by 244
Association of p300 and CBP with Simian Virus 40 Large T Antigen
Eckner, R., Ludlow, J. W., Lill, N. L., Oldread, E., Arany, Z., Modjtahedi, N., DeCaprio, J. A., Livingston, D. M., & Morgan, J. A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3454 · Cited by 243
Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein
Kitabayashi, I. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7184 · Cited by 237
The t(11;16)(q23;p13) Translocation in Myelodysplastic Syndrome Fuses the MLL Gene to the CBP Gene
Taki, T., Sako, M., Tsuchida, M., & Hayashi, Y. (1997) · Blood · doi:10.1182/blood.v89.11.3945 · Cited by 232
Ghosh, A. K., Yuan, W., Mori, Y., & Varga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203693 · Cited by 231
E2F Family Members Are Differentially Regulated by Reversible Acetylation
Marzio, G., Wagener, C., Gutierrez, M. I., Cartwright, P., Helin, K., & Giacca, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10887 · Cited by 231
CBP/p300 interact with and function as transcriptional coactivators of BRCA1
Pao, G. M., Janknecht, R., Ruffner, H., Hunter, T., & Verma, I. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1020 · Cited by 222
Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13)
Panagopoulos, I. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.4.395 · Cited by 214
MOZ is fused top300 in an acute monocytic leukemia with t(8;22)
Chaffanet, M., Gressin, L., Preudhomme, C., Soenen, V., Birnbaum, D., & P�busque, M.-J. (2000) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(200006)28:2<138::aid-gcc2>3.0.co;2-2 · Cited by 184
Oike, Y., Takakura, N., Hata, A., Kaname, T., Akizuki, M., Yamaguchi, Y., Yasue, H., Araki, K., Yamamura, K.-I., & Suda, T. (1999) · Blood · doi:10.1182/blood.v93.9.2771 · Cited by 184
Acetylation of importin-α nuclear import factors by CBP/p300
Bannister, A. J., Miska, E. A., Görlich, D., & Kouzarides, T. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00445-0 · Cited by 176
The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase
Champagne, N., Pelletier, N., & Yang, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204114 · Cited by 162
Kitabayashi, I., Aikawa, Y., Yokoyama, A., Hosoda, F., Nagai, M., Kakazu, N., Abe, T., & Ohki, M. (2001) · Leukemia · doi:10.1038/sj.leu.2401983 · Cited by 161
Computational Modeling and Experimental Analysis of Nonsense-Mediated Decay in Yeast
Cao, D., & Parker, R. (2003) · Cell · doi:10.1016/s0092-8674(03)00353-2 · Cited by 156
Petrij, F., Dauwerse, H. G., Blough, R. I., Giles, R. H., van der Smagt, J. J., Wallerstein, R., Maaswinkel-Mooy, P. D., van Karnebeek, C., van Ommen, G. B., van Haeringen, A., et al. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.3.168 · Cited by 146
CBP/p300 histone acetyl-transferase activity is important for the G1/S transition
Ait‐Si‐Ali, S., Polesskaya, A., Filleur, S., Ferreira, R., Duquet, A., Robin, P., Vervisch, A., Trouche, D., Cabon, F., & Harel‐Bellan, A. (2000) · Oncogene · doi:10.1038/sj.onc.1203562 · Cited by 145
DNA-dependent Acetylation of p53 by the Transcription Coactivator p300
Dornan, D., Shimizu, H., Perkins, N. D., & Hupp, T. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211460200 · Cited by 138
c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300
Tomita, A., Towatari, M., Tsuzuki, S., Hayakawa, F., Kosugi, H., Tamai, K., Miyazaki, T., Kinoshita, T., & Saito, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203329 · Cited by 135
Deletions on chromosome 22 in sporadic meningioma
Ruttledge, M. H., Xie, Y., Han, F., Peyrard, M., Collins, V. P., Nordenskjöld, M., & Dumanski, J. P. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870100207 · Cited by 122
Role for p300 in Stabilization of p53 in the Response to DNA Damage
Yuan, Z.-M., Huang, Y., Ishiko, T., Nakada, S., Utsugisawa, T., Shioya, H., Utsugisawa, Y., Yokoyama, K. K., Weichselbaum, R. R., Shi, Y., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.1883 · Cited by 107
Giles, R. H., Petrij, F., Dauwerse, H. G., den Hollander, A. I., Lushnikova, T., van Ommen, G. B., Goodman, R. H., Deaven, L. L., Doggett, N. A., Peters, D. J. M., et al. (1997) · Genomics · doi:10.1006/geno.1997.4699 · Cited by 88
Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16)
Giles, R. H., Dauwerse, J., Higgins, C. M., Petrij, F., Wessels, J. A., Beverstock, G. C., Döhner, H., Jotterand-Bellomo, M., Falkenburg, J. H. F., Slater, R. M., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400882 · Cited by 82
Mutation analysis of EP300 in colon, breast and ovarian carcinomas
Bryan, E. J., Jokubaitis, V. J., Chamberlain, N. L., Baxter, S. W., Dawson, E., Choong, D. Y. H., & Campbell, I. (2002) · International Journal of Cancer · doi:10.1002/ijc.10682 · Cited by 77
Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator
Suganuma, T., Kawabata, M., Ohshima, T., & Ikeda, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192586699 · Cited by 70
Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma
Takahashi, K., Kudo, J., Ishibashi, H., Hirata, Y., & Niho, Y. (1993) · Hepatology · doi:10.1002/hep.1840170508 · Cited by 60
Özdağ, H., Batley, S. J., Försti, A., Iyer, N. G., Daigo, Y., Boutell, J. M., Arends, M. J., Ponder, B. A. J., Kouzarides, T., & Caldas, C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600554 · Cited by 60
Self-citationFunction for p300 and not CBP in the apoptotic response to DNA damage
Yuan, Z.-M., Huang, Y., Ishiko, T., Nakada, S., Utsugisawa, T., Shioya, H., Utsugisawa, Y., Shi, Y., Weichselbaum, R. R., & Kufe, D. W. (1999) · Oncogene · doi:10.1038/sj.onc.1202930 · Cited by 59
Deletion Mapping of Chromosome 1p and 22q in Pheochromocytoma
Shin, E., Fujita, S., Takami, K., Kurahashi, H., Kurita, Y., Kobayashi, T., Mori, T., Nishisho, I., & Takai, S. (1993) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1993.tb00150.x · Cited by 51
Smits, P. H. M., Wit, L. D., van der Eb, A. J., & ZANTEMA, A. (1996) · PubMed · Cited by 44
Acetylation of MyoD by p300 Requires More Than Its Histone Acetyltransferase Domain
Polesskaya, A., & Harel‐Bellan, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106501200 · Cited by 43
Dual Role of p300 in the Regulation of p53 Stability
Kawai, H., Nie, L., Wiederschain, D., & Yuan, Z.-M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107770200 · Cited by 35
Ohshima, T., Suganuma, T., & Ikeda, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4389 · Cited by 33
Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines
Tillinghast, G. W., Partee, J., Albert, P., Kelley, J. M., Burtow, K. H., & Kelly, K. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10195 · Cited by 32
Lipinski, K. S., Fax, P., Wilker, B., Hennemann, H., Brockmann, D., & Esche, H. (1999) · Virology · doi:10.1006/viro.1998.9583 · Cited by 26
Analysis of the P300/CBP-Associated Factor (PCAF) Gene in Astrocytic Tumors
Nishimori, H., Nishikawa, R., Fujimaki, T., Nakagomi, T., Matsutani, M., Huang, H., & Cavenee, W. K. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006404110073 · Cited by 12
Cited by
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Phenotypic plasticity and the epigenetics of human disease
Feinberg, A. P. (2007) · Nature · doi:10.1038/nature05919 · Cited by 1,613
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Metadata
- Authors
- Iyer, N. G., Özdag, H., & Caldas, C.
- Venue
- Oncogene
- Published
- 2004-05-24
- Volume
- 23
- Issue
- 24
- Pages
- 4225-4231
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1976287566
- Cited by
- 638
- References
- 76
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.